Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial.

Background: Nebivolol is a highly cardioselective long-acting beta-blocker with vasodilating properties, which acts in part via the endothelial L-arginine/nitric oxide pathway. As an antihypertensive drug it is effective in once-daily dosage. Nebivolol has previously been shown to improve left ventricular function in patients with cardiac impairment.

[Therapy of heart failure with spirapril--the open phase of the CASSIS study. Analysis of the 2nd year extension of the CASSIS study].

The CASSIS study was a double-blind multicentric controlled Czech and Slovak study focused on treatment of chronic heart failure with the ACE inhibitor spirapril; it was conducted for 12 weeks. The present work analyzes the second year of the extended open part of the study when all patients (n = 168) were treated with 3 mg or 6 mg spirapril. A small proportion of the patients was treated with 12 mg spirapril.

[A Czech and Slovak interventional study of spirapril (the CASSIS study). A randomized, double-blind, multicenter, placebo-controlled study in chronic heart failure].

Spirapril, an ACE-inhibitor without the SH group was tested in a randomized double-blind multicentric study in patients with chronic symptomatic heart failure (NYHA II-IV). After a 1-4-week initial stage with placebo the patients were randomized into five groups: the first was given placebo, the second one spirapril 1.5 mg, the third one spirapril 3 mg, the fourth one spirapril 6 mg and the fifth one 5 and later 10 mg for a period of 12 weeks.

[Corotenol, its effectiveness and tolerance in light of new studies].

The effectiveness and tolerance of Corotenol of Mepha Co. was investigated in two studies under conditions of common ambulatory practice of specialists in internal medicine and general practitioners in patients suffering from mild to moderate hypertension and/or ischaemic heart disease. A surprising finding was a high percentage of patients with an inadequately controlled blood pressure before enlistment into the study.

Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure.

A randomized, double-blind, placebo- and active-controlled multicentre study with spirapril, a new angiotensin-converting enzyme inhibitor (ACEI), has been conducted in patients with chronic congestive heart failure (CHF) of NYHA classes II-IV. After a placebo run-in period of 1-4 weeks, patients were randomly assigned to one of five treatment groups: placebo (n = 48), spirapril 1.5 mg (n = 48), spirapril 3 mg (n = 53), spirapril 6 mg (n = 51) or enalapril 5/10 mg (n = 48).

[24-hour effect and tolerance for perindopril (Prestarium) in mild and moderate essential hypertension].

A multicentre investigation of antihypertensive treatment by perindopril was conducted in three centres of Czechoslovakia. The investigation comprised 51 patients with mild to moderate essential hypertension (diastolic pressure 95-115 mmHg) who were taking perindopril for a period of three months, the initial dose being 4 mg (1 tablet per day). If the blood pressure did not drop to normal levels (dBP < 90 mmHg), the dose was increased to 8 mg after 1 month and if after 2 months of treatment the blood pressure did not reach normal levels, a thiazide diuretic was added.

[Clinical evaluation and comparison of the effects of Dobuject and Dobutrex after open heart surgery].

The paper list the results of a comparative study on the clinical and haemodynamic effects of 2 medicaments, registered in the Czechoslovak Socialist Republic, i. e. dobutamine hydrochloride, Dobutrex the Federal Republic of Germany) and Dobuject (Loiras, Finland).

Bopindolol in the treatment of hypertension: a double blind study comparing bopindolol and metoprolol.

The article presents the experience gained with a new betablocker- bopindolol-in the treatment of hypertension. Using a three-month double blind study conducted in 2 centres, the antihypertensive effect of bopindolol and metoprolol was compared in a total of 86 patients. The incidence of undesirable effects was determined, and biochemical parameters before and after therapy were followed up.

An evaluation of the leading patent equivalents services.

Patent equivalent services are useful tools for identifying patent families. A patent family consists of a group of patents in various countries which cover the same invention. The patent equivalents services provided by the three leading suppliers--Chemical Abstracts Service, Derwent Publications Ltd.